Integrative in-silico screening for SGLT1 and GLUT5 modulators

Overview

This research offering delivers a structured in-silico screening pipeline designed to identify and rank potential modulators of SGLT1 and GLUT5, two key transporters involved in glucose and fructose uptake. By combining high-throughput virtual screening (HTVS), molecular docking, pharmacophore modeling, machine learning-based filtering, and molecular dynamics (MD) simulations, the approach accelerates the discovery of compounds that can inhibit or activate these transporters. The pipeline also incorporates ADME/toxicity prediction to prioritize candidates with favorable safety profiles, reducing the time and cost of downstream experimental work.

The solution targets researchers and companies working in metabolic disease, nutrition, and pharmaceutical development who need a rapid, cost-effective method to identify transporter modulators before committing to in-vitro and in-vivo validation.

Technical specifications

Pipeline components:

• High-throughput virtual screening (HTVS) to filter large compound libraries
• Molecular docking to evaluate binding interactions with SGLT1 and GLUT5
• Pharmacophore modeling validated using decoy sets for reliability
• Machine learning-based ranking of compounds by predicted safety and efficacy
• ADME/toxicity prediction to assess pharmacokinetic and safety profiles
• Molecular dynamics simulations and in-silico assays for validation of top candidates
• All computational steps performed in triplicate with statistical analysis for reproducibility

Compound library and downstream readiness:

• A curated compound library is prepared and ready for further in-vitro studies
• Future validation plan includes establishing human cell lines expressing SGLT1 and GLUT5
• In-vitro screening assays to be optimized for efficiency, robustness, and reproducibility
• Evaluation of GRAS ingredients, drugs, and other compounds for transporter effects
• Timeline for full validation: approximately 8 to 10 months

Technology readiness level

The in-silico screening methodology has been established and validated through a standard computational pipeline. Pharmacophore models have been developed and tested with decoy sets, and all in-silico techniques have been performed in triplicate with statistical analysis to ensure reliability. The compound library is prepared for further in-vitro evaluation. The next stage involves experimental validation of top-ranked compounds and development of a comprehensive database. The current readiness level reflects a validated computational framework ready for collaborative experimental extension.